First design
Site theme
Sign up or sign in to sign up for discussions!
Russian President Vladimir Putin announced wednesday the timing of the dubious approval of a COVID-19 vaccine that has been evaluated in clinical trials.
The vaccine, called EpiVacCorone, is thought to be an artificial peptide-based vaccine that uses fragments of the SARS-CoV-2 pandemic virus to stimulate protective immune responses in vaccinated individuals. Laboratory of Soviet biological weapons studies.
Like the first vaccine approved through Russia, the question of whether EpiVacCorona is really safe and effective is absolutely unknown. At a televised press conference, Putin said the first essays involving a hundred more people had been successful, but researchers have not. published any knowledge about the protection or effectiveness of these trials. Russian fitness officials said they were still reviewing the vaccine for “protection and quality,” but refused to provide more data on the vaccine, knowledge or approval process.
In addition, EpiVacCorona has not yet participated in the largest clinical trials needed for protection and efficacy. In general, knowledge of complex clinical trials (Phase III trials) is required for popular regulatory approval. These trials tend to involve tens of thousands of participants, who are monitored intensively for months to evaluate the effectiveness of the vaccine in preventing infections and to monitor rare side effects.
However, Putin promorated the new vaccine at the press conference, revealing that Deputy Prime Minister Tatyana Golikova and Russia’s leading protection supervisor Anna Popova won doses of EpiVacCorona in a clinical trial.
The scarcity of knowledge about EpiVacCorona echoes what was warned in August, when Russia approved its first COVID-19 vaccine, Sputnik V. This vaccine was also approved without published knowledge after being tested in only 76 people. The first effects of the trials have since been published in the vaccine, however, the researchers temporarily noticed peculiarities in the knowledge. Sputnik V is currently in Phase III primary trials.
And, like EpiVacCorona, Putin announced Sputnik V’s approval while signaling early, high-profile vaccines. Putin revealed that one of his own daughters had won a dose of the vaccine.
Join Ars Orbital Transmission mail for weekly updates to your inbox.